Published in Medical Letter on the CDC and FDA, January 1st, 2006
The SPA letter provides a written agreement between Dendreon and the FDA concerning the trial design and outlines definitive clinical objectives and data analyses.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.